Request Demo
Recent blog posts
Latest Hotspot
8 min read
Trigeminal Neuralgia Report 2026: Sodium Channels and Whitespace
21 July 2026
Trigeminal Neuralgia Report 2026: Sodium Channels and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Diabetic Peripheral Neuropathy Report 2026: SARM1, Nav1.8 and Trials
21 July 2026
Diabetic Peripheral Neuropathy Report 2026: SARM1, Nav1.8 and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Neuropathic Pain Strategy Report 2026: Nav1.7, Nav1.8 and Trials
21 July 2026
Neuropathic Pain Strategy Report 2026: Nav1.7, Nav1.8 and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Restless Legs Syndrome Strategy Report 2026: D2/D3 and Whitespace
21 July 2026
Restless Legs Syndrome Strategy Report 2026: D2/D3 and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Insomnia Indication Strategy Report 2026: Orexin, GABA and Trials
21 July 2026
Insomnia Indication Strategy Report 2026: Orexin, GABA and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Narcolepsy Indication Strategy Report 2026: OX2R, H3, Trials and Deals
21 July 2026
Narcolepsy Indication Strategy Report 2026: OX2R, H3, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Sodium Chlorite Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Sodium Chlorite: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Exordia Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Exordia: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Atazanavir Sulfate/Ritonavir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Atazanavir Sulfate/Ritonavir: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Bepirovirsen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Bepirovirsen: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Sodium Dichloroacetate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Sodium Dichloroacetate: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Fanregratinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Fanregratinib: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.